CPI-17 Antibody (A-7): sc-28378

CPI-17 Antibody (A-7) is a mouse monoclonal IgG2b antibody that detects CPI-17 in mouse, rat, human, and porcine samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CPI-17 is a crucial phosphorylation-dependent inhibitory protein that plays a significant role in regulating smooth muscle contraction by inhibiting myosin phosphatase activity. CPI-17 is primarily located in the cytoplasm of smooth muscle cells, where CPI-17 modulates the contractile response by enhancing calcium sensitivity. This localization is vital because CPI-17 effectively interacts with myosin phosphatase and other signaling molecules, thereby influencing smooth muscle tone and vascular function. Notably, CPI-17 is phosphorylated at Threonine 38 by various kinases, including protein kinase C and Rho-kinase, which increases inhibitory potency and contributes to the physiological processes of smooth muscle contraction. CPI-17′s ability to undergo dual phosphorylation at Serine 12 and Threonine 38 by the MYPT-associated kinase, M110 kinase, further underscores CPI-17′s importance in smooth muscle signaling pathways. With robust reactivity and versatility in various applications, anti-CPI-17 antibody (A-7) serves as an essential tool for researchers studying smooth muscle physiology and related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CPI-17 Antibody (A-7) References:

1. Phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by protein kinase N.  |  Hamaguchi, T., et al. 2000. Biochem Biophys Res Commun. 274: 825-30. PMID: 10924361
2. Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase.  |  Jin, H., et al. 2006. Nature. 442: 576-9. PMID: 16885985
3. Expression of CPI-17 in smooth muscle during embryonic development and in neointimal lesion formation.  |  Kim, JI., et al. 2009. Histochem Cell Biol. 132: 191-8. PMID: 19437030
4. Dexmedetomidine-Induced Contraction Involves CPI-17 Phosphorylation in Isolated Rat Aortas.  |  Ok, SH., et al. 2016. Int J Mol Sci. 17: PMID: 27706026
5. CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins.  |  Riecken, LB., et al. 2016. Oncotarget. 7: 78242-78254. PMID: 27793041
6. The essential role of phospho-T38 CPI-17 in the maintenance of physiological blood pressure using genetically modified mice.  |  Yang, Q., et al. 2018. FASEB J. 32: 2095-2109. PMID: 29229685
7. The Effect of Galangin on the Regulation of Vascular Contractility via the Holoenzyme Reactivation Suppressing ROCK/CPI-17 rather than PKC/CPI-17.  |  Yoon, HJ., et al. 2022. Biomol Ther (Seoul). 30: 145-150. PMID: 34231489
8. The Effect of Luteolin on the Modulation of Vascular Contractility via ROCK and CPI-17 Inactivation.  |  Yoon, HJ., et al. 2023. Biomol Ther (Seoul). 31: 193-199. PMID: 36065763
9. Phosphorylated CPI-17 and MLC2 as Biomarkers of Coronary Artery Spasm-Induced Sudden Cardiac Death.  |  Dong, Y., et al. 2024. Int J Mol Sci. 25: PMID: 38474189
10. Effect of Kaempferol on Modulation of Vascular Contractility Mainly through PKC and CPI-17 Inactivation.  |  Yoon, HJ., et al. 2024. Biomol Ther (Seoul). 32: 361-367. PMID: 38589300

The preferred CPI-17 antibody is CPI-17 Antibody (C-1): sc-365841.